Coya Therapeutics (COYA) News Today → America’s worst nightmare? (From Porter & Company) (Ad) Free COYA Stock Alerts $8.08 -0.13 (-1.58%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 11 at 1:18 AM | americanbankingnews.comCoya Therapeutics (NASDAQ:COYA) Stock Rating Reaffirmed by Chardan CapitalMay 10, 2024 | finance.yahoo.comCoya Therapeutics Reports First Quarter 2024 Financial ResultsMay 10, 2024 | marketbeat.comCoya Therapeutics' (COYA) Buy Rating Reaffirmed at Chardan CapitalChardan Capital reissued a "buy" rating and set a $14.00 price target on shares of Coya Therapeutics in a research report on Thursday.May 10, 2024 | msn.comCOYA Stock Earnings: Coya Therapeutics Misses EPS for Q1 2024May 9, 2024 | businesswire.comCoya Therapeutics Provides a Corporate Update and Reports Unaudited First Quarter 2024 Financial ResultsMay 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Coya Therapeutics Amid Promising ALS Biomarker Data and Treatment PotentialMay 1, 2024 | seekingalpha.comWhy Coya Therapeutics Is A Smart Speculative Buy For Neurodegenerative DiseasesApril 29, 2024 | marketbeat.comCoya Therapeutics (NASDAQ:COYA) Earns "Buy" Rating from Chardan CapitalChardan Capital reiterated a "buy" rating and set a $14.00 target price on shares of Coya Therapeutics in a research report on Monday.April 26, 2024 | businesswire.comCoya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center SymposiumApril 23, 2024 | finance.yahoo.comCoya Therapeutics, Inc. (COYA)April 22, 2024 | businesswire.comCoya Therapeutics to Participate in the Mizuho Neuroscience SummitApril 18, 2024 | businesswire.comCoya Therapeutics to Participate in the 3rd Annual ALS Drug Development SummitApril 15, 2024 | finance.yahoo.comCoya Therapeutics, Inc. (COYA) Interactive Stock Chart - Yahoo FinanceApril 10, 2024 | marketbeat.comCoya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Up 309.2% in MarchCoya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 191,100 shares, a growth of 309.2% from the March 15th total of 46,700 shares. Based on an average daily trading volume, of 94,200 shares, the days-to-cover ratio is presently 2.0 days. Currently, 1.5% of the company's stock are short sold.April 8, 2024 | businesswire.comCoya Therapeutics Scientific Advisory Board Chairman Dr. Stanley Appel to Present Updated ALS Biomarker Data at the 2nd Annual Johnson Center SymposiumMarch 28, 2024 | marketbeat.comShort Interest in Coya Therapeutics, Inc. (NASDAQ:COYA) Rises By 123.4%Coya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) was the target of a large growth in short interest in March. As of March 15th, there was short interest totalling 46,700 shares, a growth of 123.4% from the February 29th total of 20,900 shares. Based on an average daily volume of 92,200 shares, the short-interest ratio is presently 0.5 days. Approximately 0.4% of the company's shares are short sold.March 27, 2024 | finance.yahoo.comWe're Not Very Worried About Coya Therapeutics' (NASDAQ:COYA) Cash Burn RateMarch 21, 2024 | finance.yahoo.comCoya Therapeutics Inc (COYA) Reports Fiscal 2023 Financial Results and Corporate UpdatesMarch 20, 2024 | marketbeat.comCoya Therapeutics (NASDAQ:COYA) PT Raised to $14.00Chardan Capital raised their price objective on shares of Coya Therapeutics from $11.00 to $14.00 and gave the company a "buy" rating in a research note on Wednesday.March 19, 2024 | investorplace.comCOYA Stock Earnings: Coya Therapeutics Reported Results for Q4 2023March 19, 2024 | finance.yahoo.comCoya Therapeutics Provides a Corporate Update and Reports Fiscal 2023 Financial ResultsMarch 18, 2024 | marketbeat.comCoya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Down 6.3% in FebruaryCoya Therapeutics, Inc. (NASDAQ:COYA - Get Free Report) was the recipient of a large decline in short interest in February. As of February 29th, there was short interest totalling 20,900 shares, a decline of 6.3% from the February 14th total of 22,300 shares. Based on an average trading volume of 70,500 shares, the short-interest ratio is presently 0.3 days. Currently, 0.2% of the shares of the stock are short sold.March 14, 2024 | investing.comCoya presents promising ALS biomarker data at conferenceMarch 13, 2024 | msn.comNew treatment for ALS provides hope for Maine families battling diseaseMarch 12, 2024 | finance.yahoo.comCoya Therapeutics Presents ALS Biomarker Data at Society of Neuroimmune Pharmacology ConferenceMarch 12, 2024 | finance.yahoo.comCoya Therapeutics to Participate in BTIG Fireside DiscussionMarch 10, 2024 | markets.businessinsider.comBuy Recommendation for Coya Therapeutics on Promising Neurodegenerative Disease Treatment ApproachMarch 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Dyne Therapeutics: Promising Clinical Data and Solid Financial Position Fuel OptimismFebruary 29, 2024 | finance.yahoo.comCoya Therapeutics to Present Data on Immune System and Regulatory T Cell (Treg) Contributions in Frontotemporal Dementia (FTD) Patients at AD/PD 2024 ConferenceFebruary 22, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Denali Therapeutics (DNLI) and Treace Medical Concepts (TMCI)February 22, 2024 | msn.comCoya Inches up Ahead of ALS AddressFebruary 22, 2024 | businesswire.comCoya Therapeutics to Present Novel Biomarker Survival Data in Large Cohort of ALS (Amyotrophic Lateral Sclerosis) Patients at Society of Neuroimmune Pharmacology ConferenceFebruary 21, 2024 | finance.yahoo.comCoya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer’s Disease and Coya’s Pathway to a "Pipeline in a Product"February 21, 2024 | businesswire.comCoya Therapeutics Issues Letter to Stockholders Highlighting Expansion of COYA 302 into Alzheimer's Disease and Coya's Pathway to a “Pipeline in a Product”February 13, 2024 | finance.yahoo.comCoya Therapeutics Licenses Intellectual Property Rights for Use of Next Generation Immune Modulatory Biologics in Combination with COYA 301 to Enhance Regulatory T Cells (Tregs) in Inflammatory DiseasesFebruary 5, 2024 | benzinga.comCoya Therapeutics Secures Key Financing In Its Fight Against Myriad DiseasesFebruary 1, 2024 | markets.businessinsider.comBuy Rating Affirmed for Coya Therapeutics Amid Promising Drug Development and Regulatory MilestonesJanuary 29, 2024 | finance.yahoo.comCoya Therapeutics SAB Chairman Dr. Stanley Appel, M.D. Selected as Speaker at the Society of Neuroimmune Pharmacology ConferenceJanuary 18, 2024 | finance.yahoo.comCoya Therapeutics to Participate in Upcoming Chardan Biotech Leadership Call SeriesJanuary 16, 2024 | finance.yahoo.comCoya Therapeutics Announces Pipeline Expansion of COYA 302 to Include Frontotemporal Dementia and Parkinson’s Disease in Addition to Amyotrophic Lateral SclerosisJanuary 16, 2024 | finance.yahoo.comDISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed FinancingJanuary 5, 2024 | markets.businessinsider.comCoya Therapeutics Plans COYA 302 IND Application In Q2 - Quick FactsJanuary 5, 2024 | finance.yahoo.comCoya Therapeutics Announces Successful Pre-IND and Type C Meetings with the FDA to Advance the Development of COYA 302 for Treatment of Amyotrophic Lateral Sclerosis (ALS)January 4, 2024 | markets.businessinsider.comOptimistic Outlook on Dyne Therapeutics Backed by Promising Early Trial ResultsJanuary 4, 2024 | msn.comCoya Therapeutics files to sell 4.69M shares for holdersDecember 21, 2023 | benzinga.comCoya Therapeutics Stock (NASDAQ:COYA) Dividends: History, Yield and DatesDecember 20, 2023 | finance.yahoo.comMr. Wilbur L. Ross, Former United States Secretary of Commerce, Joins Board of Coya Therapeutics, Inc.December 14, 2023 | finance.yahoo.comDavid Einhorn's Greenlight Capital Boosts Coya Therapeutics HoldingDecember 14, 2023 | finance.yahoo.comDavid Einhorn's Greenlight Capital Adds Coya Therapeutics to Its PortfolioDecember 14, 2023 | markets.businessinsider.comStrong Buy Rating for Coya Therapeutics Amid Enhanced Financial Health and Strategic Partnerships Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Guard Against the Coming Financial Upheaval (Ad)America’s Most Shocking Financial Story… Behind closed doors in D.C., there is a dark political and economic plot underway. That’s why if you have any savings in the bank or own any assets you want to protect, you must watch this new documentary before it’s too late. You can stream it for free right here. COYA Media Mentions By Week COYA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. COYA News Sentiment▼0.280.57▲Average Medical News Sentiment COYA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. COYA Articles This Week▼82▲COYA Articles Average Week Get Coya Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for COYA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Cartesian Therapeutics News Today Immunic News Today Abeona Therapeutics News Today Cellectar Biosciences News Today Vistagen Therapeutics News Today OptiNose News Today Societal CDMO News Today Rezolute News Today Karyopharm Therapeutics News Today Relmada Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:COYA) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsElon’s New Device is About to Shock the WorldInvestorPlaceTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaCharles Payne Demystifies OptionsUnstoppable ProsperityForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressGold ManiaStansberry ResearchNot Trump. Not Biden. But ___________.The Freeport SocietyThe only AI company you should be looking atBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
